Amgen and AstraZeneca present new combo data for extensive-stage small cell lung cancer at ESMO
Day two of the European Society for Medical Oncology meeting in Madrid saw nearly 40,000 attendees gathering for the latest cancer research updates, as reported in the STAT+ newsletter.
The session featured new data on the combination of Amgen's Imdelltra and AstraZeneca's Imfinzi in patients with extensive-stage small cell lung cancer, marking a notable development in the therapeutic landscape for this aggressive disease.
In addition to the combo data, the conference highlighted a high‑profile "presidential" presentation from Moderna and Merck, underscoring the breadth of innovation showcased at ESMO. The newsletter promises further coverage as the meeting concludes.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: The ESMO presentation everyone’s been waiting for”
read at STAT ↗
comments(0)
5-min edit window · permanent after that